Oculis SA has agreed to license a topical anti-TNF alpha antibody from Novartis
Oculis SA has entered into an agreement to license a novel topical anti-TNF alpha antibody from Novartis.
The compound, LME 636, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Efficacy and safety were evaluated in three clinical trials.
Dr Riad Sherif, Oculis CEO, said: “This agreement is part of our ongoing strategy to access multiple sources of technologies and compounds that bolster our portfolio of innovative products to treat eye diseases.”